| Literature DB >> 25610774 |
J Yankam Njiwa1, K R Gray2, N Costes3, F Mauguiere4, P Ryvlin5, A Hammers1.
Abstract
PURPOSE: We have previously shown that an imaging marker, increased periventricular [(11)C]flumazenil ([(11)C]FMZ) binding, is associated with failure to become seizure free (SF) after surgery for temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS). Here, we investigated whether increased preoperative periventricular white matter (WM) signal can be detected on clinical [(18)F]FDG-PET images. We then explored the potential of periventricular FDG WM increases, as well as whole-brain [(11)C]FMZ and [(18)F]FDG images analysed with random forest classifiers, for predicting surgery outcome.Entities:
Keywords: FDG-PET; FMZ-PET; Hippocampal sclerosis; Periventricular white matter signal increases; Random forests; Surgery outcome
Mesh:
Substances:
Year: 2014 PMID: 25610774 PMCID: PMC4299974 DOI: 10.1016/j.nicl.2014.11.013
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Clinical data for 16 patients with refractory mTLE and HS. Upper half: seizure free patients; lower half: non-seizure free patients. Imaging based predictors for seizure status are colour-coded, with green indicating that the particular marker correctly predicted the individual patient's outcome class according to the method used in that column (see text for details).
| Patient | Age/sex | Onset/duration of epilepsy (years) | HS | Follow-up (months) | Medication at operation. *: reduced. **: stopped (medication restarted) | Outcome (Engel class) | FDG hypometabolism on SPM | [11C]FMZ-PET increases in periventricular areas (threshold = 0.01, | [18F]FDG-PET increases in periventricular areas (threshold = 0.01, | RF prediction (FMZ) | RF prediction (FDG) | Additional information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 24/f | 6/18 | L | 31 | LEV, LTG* | IA | Yes | None | L ant front lobe | True | False | L temporal–occipital dysplasia |
| #2 | 22/f | 2/20 | L | 58 | CBZ, TPM, CLB** | IA | Yes | None | None | False | False | |
| #3 | 27/m | 4/23 | L | 35 | CBZ, VPA, CLB** | IA | Yes | None | None | True | True | |
| #4 | 36/f | 3/33 | L | 98 | CBZ, LTG, TPM** | IA | Yes | None | L ant front lobe | True | True | L temporal pole signal abnormalities + discrete dysgenesis of left amygdala |
| #5 | 46/f | 12/34 | L | 52 | PB, PRG, LEV* | IA | No | None | R ant front lobe | True | True | |
| #6 | 26/f | 5/21 | R | 112 | CBZ, CLB, PB* | IA | No | R lat of ventricle | L lateral of ventricle | True | False | R temporal pole signal abnormalities |
| #7 | 48/f | 6/42 | R | 81 | CBZ, CLB** | IA | Yes | None | None | True | True | |
| #8 | 30/f | 5/25 | R | 24 | CBZ, TPM, CLB, LEV** | IA | Yes | None | None | True | False | |
| #9 | 46/f | 33/13 | R | 23 | PHT, LEV, PB** | IB | Yes | None | Lateral of posterocentral portion of R lateral ventricle | True | False | |
| #10 | 36/f | 3/33 | R | 116 | CBZ, PB, CLB | IVB | No | None | None | True | True | Seizure onset right temporal and right insular on SEEG |
| #11 | 29/f | 4/25 | R | 44 | CBZ, CLB** | IIA | Yes | None | None | True | True | Small symmetric hippocampi and temporal pole signal abnormalities on MRI (FDG, SEEG unilateral R) |
| #12 | 32/m | 5/27 | L | 119 | PB, CLB** (LEV, CLB) | IIA | No | Widespread WM increases with the maximum L ant of frontal horn | Widespread WM increases with the maximum R lat ventricle | True | True | |
| #13 | 32/f | 11/21 | L | 89 | CLB, CBZ** (CBZ, PB) | IID | No | Lateral of anterocentral portion of R frontal horn | R anterior of frontal horn | False | True | |
| #14 | 22/m | 9/13 | L | 72 | CBZ, TPM, PB, CLB** | ID | Yes | Lateral of posterocentral portion of L lateral ventricle | L ant front lobe | True | True | |
| #15 | 39/m | 1/38 | L | 67 | TPM, PB* | IIA | No | Lateral and inferior of L ventricle where temporal and occipital horns originate | Lateral postorocentral portion of R lateral | True | False | |
| #16 | 41/f | 3/38 | R | 78 | LTG, CBZ, PB* | IC | No | Lateral and inferior of R ventricle where temporal and occipital horns originate | None | True | True | Moderated gliosis R temporal pole, L ventricular enlargement |
AP = amisulpride, AZL = alprazolam, PB = phenobarbital, CBZ = carbamazepine, CLB = clobazam, CP = codeine paracetamol, DHGT = dihidroergotamine, EXD = enrofloxacine+diclofenac Enromax, FA = folic acid, GBP = gabapentin, GVG = vigabatrin, HDZ = hydroxyzine, LEV = levetiracetam, LTG = lamotrigine, OXC = oxcarbazepine, PB = phenobarbital, PBA = phenobarbital with amphetamine, PHT = phenytoin, PPN = pipampérone, PVT = pravastatin, PX = paroxétine, PZ = Prozac, TGB = tiagabine, TPM = topiramate, VPA = valproic acid.
Postoperative outcomes for non-seizure free patients are given in the footnotes, including times when the outcome class changed. [11C]FMZ-PET results were previously presented (Yankam Njiwa, 2013 #6038) and are repeated here for comparison.Clusters are characterized by peak voxel z score (MNI coordinates), and cluster extent.
M = male, f = female, HS = hippocampal sclerosis.1IB at 5 months and IA at 17 months. 2Never seizure free. 3IB at 5, 10, 23 months, ID at 16 months and IA at 29 and 35 months. 4IA until 110 months. 5IA at 19 months and IID at 31 months. 6ID at 60 months. 7IIA at 67 months. 8IC at 12 and 21 months.
Global values (mean ± SD), in Bq/ml, computed for summed radioactivity images (FMZ) and FDG static images, before and after normalization. In brackets are the student test values of comparison of different patient groups and control group. The absolute difference in values before and after normalization is due to matrix size differences.
| FDG | FMZ | |||||
|---|---|---|---|---|---|---|
| NSF | SF | Controls | NSF | SF | Controls | |
| Before normalization | 2064 ± 946 ( | 2290 ± 986 ( | 2998 ± 652 | 1492 ± 300 ( | 1562 ± 207 ( | 1778 ± 256 |
| After normalization | 3268 ± 1807 ( | 3233 ± 1360 ( | 4154 ± 932 | 2183 ± 395 ( | 2202 ± 279 ( | 2409 ± 335 |
Fig. 1Periventricular increases and unmasked statistical results overlaid onto the SPM8 T1-weighted template. FDG results obtained for this study; FMZ results from Yankam Njiwa et al. (2013) and shown for direct comparison. (a) Increases in non-seizure free patients (NSF; not Engel IA) compared to seizure-free patients; ipsilateral, left side, (zmax = 2.69, CE = 0.56 cm3) and contralateral (zmax = 4.2, CE = 0.9 cm3) for FMZ and ipsilateral (zmax = 3.66, CE = 1.1 cm3), contralateral (zmax = 3.37, CE = 0.4 cm3) for FDG. (b) Seizure free (SF; Engel class IA) patients, compared to controls (zmax = 3.31, CE = 0.25 cm3, ipsilateral) for FMZ and (zmax = 4.16, CE = 2.12 cm3, ipsilateral) for FDG. The apparent increase near the superior sagittal sinus is a normalization artefact appearing in both modalities. (c) NSF patients compared to controls (zmax = 5.25, CE = 5.25 cm3, ipsilateral) for FMZ and (zmax = 4.68, CE = 5.2 cm3, contralateral) for FDG. (d) Periventricular signal increases in an individual patient (#15), with a suboptimal outcome, for FMZ (zmax = 4.01, CE = 3 cm3, ipsilateral), and for FDG (zmax = 5.11, CE = 7.3 cm3, contralateral). Significant clusters are pointed with green arrows.
Evaluation of the age at seizure onset, the duration of epilepsy and the age at operation as potential non-imaging predictors for epilepsy surgery outcome, in terms of median, interquartile distance, and Mann–Whitney U test (MWUT) values.
| Mean[interquartile distance] | |||
|---|---|---|---|
| Predictor | Age at onset | Duration of epilepsy | Age at operation |
| NSF | 4.5 [6.5] | 26 [15.3] | 34 [8.3] |
| SF | 5.0 [2.3] | 24 [12.5] | 28.5 [13] |
| MWUT (two tailed) | 32.5 ( | 32.5 ( | 38.5 ( |
Test performance of the SPM-based assessment of periventricular increases. SF, seizure free (n = 8); NSF, not seizure free (n = 8); FMZ [11C]flumazenil PET; FDG [18F]FDG PET. The cells with a grey background indicate patients correctly classified.
Fig. 2Feature importances for differentiating between three clinical groups using voxel based FDG-PET (bottom) and FMZ-PET (top). Voxels important for distinguishing patients from controls are overlaid onto an MNI-space FMZ-PET template (top) and FDG-PET template (bottom). Left column, non-seizure free patients; right column, seizure free patients.
Performance results of the RF classifier for binary classifications. Mean ± SD accuracy, sensitivity and specificity for summed radioactivity images (FMZ) and FDG static images. Performances are averaged over the number of trees for each RF (1000:1000:10,000). NSF = not seizure free, SF = seizure free, C = controls. Performance values of the RF classifier in classifying NSF/SF patients versus controls and in identifying NSF patients versus SF patients.
| FDG | FMZ | |||||
|---|---|---|---|---|---|---|
| NSF/SF | NSF/C | SF/C | NSF/SF | NSF/C | SF/C | |
| Accuracy | 0.36 ± 0.03 | 0.66 ± 0.001 | 0.53 ± 0.02 | 0.40 ± 0.06 | 0.83 ± 0.01 | 0.82 ± 0.01 |
| Sensitivity | 0.33 ± 0.06 | 0.74 ± 0.04 | 0.5 ± 0.00 | 0.20 ± 0.06 | 0.76 ± 0.04 | 0.76 ± 0.04 |
| Specificity | 0.40 ± 0.05 | 0.63 ± 0.00 | 0.53 ± 0.03 | 0.54 ± 0.08 | 0.85 ± 0.01 | 0.83 ± 0.01 |